Clovis Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>CO</div>
CLVS -- USA Stock  

USD 6.10  0.15  2.40%

Clovis Oncology Accrued Expenses Turnover is relatively stable at the moment as compared to the past year. Clovis Oncology reported last year Accrued Expenses Turnover of 1.78. As of 03/19/2021, Cash and Equivalents Turnover is likely to grow to 0.88, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (357.2 M). The fundamental reasoning behind this short post is to break down our forecasting of Clovis for retail investors. We will try to forecast Clovis Oncology outlook for April.
Published over three weeks ago
View all stories for Clovis Oncology | View All Stories
Our latest forecast of Clovis (NASDAQ:CLVS)
Clovis Oncology is OVERVALUED at 6.64 per share with modest projections ahead. Over 61.0% of Clovis Oncology shares are held by institutions such as insurance companies. Institutional ownership of Clovis Oncology refers to the amount of Clovis Oncology equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Clovis, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Clovis Oncology. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Clovis Oncology

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Clovis Oncology's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Clovis Oncology in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Clovis Oncology. Your research has to be compared to or analyzed against Clovis Oncology's peers to derive any actionable benefits. When done correctly, Clovis Oncology's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Clovis Oncology.

How important is Clovis Oncology's Liquidity

Clovis Oncology financial leverage refers to using borrowed capital as a funding source to finance Clovis Oncology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Clovis Oncology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Clovis Oncology's total debt and its cash.

How Clovis utilizes its cash?

To perform a cash flow analysis of Clovis Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Clovis Oncology is receiving and how much cash it distributes out in a given period. The Clovis Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Clovis Oncology Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Clovis Oncology reported last year Net Cash Flow from Operations of (252.73 Million)

Another angle On Clovis Oncology

Clovis Oncology is displaying above-average volatility over the selected time horizon. Investors should scrutinize Clovis Oncology independently to ensure intended market timing strategies are aligned with expectations about Clovis Oncology volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clovis Oncology's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clovis Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Returns Breakdown

Return on Investment(68.16)
Return on Assets(0.66)
Return on Equity2.92
Return Capital(0.49)
Return on Sales(2.23)

Are Clovis Oncology technical ratios showing a relapse?

The sortino ratio is down to 0.15 as of today. Clovis Oncology is displaying above-average volatility over the selected time horizon. Investors should scrutinize Clovis Oncology independently to ensure intended market timing strategies are aligned with expectations about Clovis Oncology volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Clovis Oncology's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Clovis Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Clovis Oncology

While some companies under the biotechnology industry are still a bit expensive, Clovis Oncology may offer a potential longer-term growth to retail investors. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Clovis as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Clovis Oncology.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Clovis Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com